Your browser doesn't support javascript.
loading
PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.
Delyon, Julie; Biard, Lucie; Renaud, Marion; Resche-Rigon, Matthieu; Le Goff, Jérôme; Dalle, Stéphane; Heidelberger, Valentine; Da Meda, Laetitia; Toullec, Laurie; Carcelain, Guislaine; Mourah, Samia; Caillat-Zucman, Sophie; Allain, Vincent; Battistella, Maxime; Lebbe, Céleste.
Afiliação
  • Delyon J; Université Paris Cité, INSERM U976 HIPI, Paris, France; Department of Dermatology, DMU ICARE, AP-HP Saint-Louis Hospital, Paris, France. Electronic address: julie.delyon@aphp.fr.
  • Biard L; Université Paris Cité, INSERM U1153, Team ECSTRRA, Paris, France; Department of Biostatistics and Medical Information, AP-HP Saint-Louis Hospital, Paris, France.
  • Renaud M; Department of Dermatology, DMU ICARE, AP-HP Saint-Louis Hospital, Paris, France.
  • Resche-Rigon M; Université Paris Cité, INSERM U1153, Team ECSTRRA, Paris, France; Department of Biostatistics and Medical Information, AP-HP Saint-Louis Hospital, Paris, France.
  • Le Goff J; Université Paris Cité, INSERM U976 HIPI, Paris, France; Department of Virology, AP-HP Saint-Louis Hospital, Paris, France.
  • Dalle S; Department of Dermatology, Hôpital Lyon-Sud, Immucare, Centre de Recherche en Cancérologie de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
  • Heidelberger V; Department of Dermatology, AP-HP Hôpital Avicenne, Bobigny, France.
  • Da Meda L; Department of Dermatology, DMU ICARE, AP-HP Saint-Louis Hospital, Paris, France.
  • Toullec L; Université Paris Cité, INSERM U976 HIPI, Paris, France; Department of Immunology and Histocompatibility, DMU PRISME, AP-HP Saint-Louis Hospital, Paris, France.
  • Carcelain G; Université Paris Cité, INSERM U976 HIPI, Paris, France; Department of Immunology, AP-HP Robert Debré hospital, Paris France.
  • Mourah S; Université Paris Cité, INSERM U976 HIPI, Paris, France; Department of Genomics of Solid Tumors and Pharmacology, AP-HP Saint-Louis Hospital, Paris, France.
  • Caillat-Zucman S; Université Paris Cité, INSERM U976 HIPI, Paris, France; Department of Immunology and Histocompatibility, DMU PRISME, AP-HP Saint-Louis Hospital, Paris, France.
  • Allain V; Université Paris Cité, INSERM U976 HIPI, Paris, France; Department of Immunology and Histocompatibility, DMU PRISME, AP-HP Saint-Louis Hospital, Paris, France.
  • Battistella M; Université Paris Cité, INSERM U976 HIPI, Paris, France; Department of Pathology, AP-HP Saint-Louis Hospital, Paris, France.
  • Lebbe C; Université Paris Cité, INSERM U976 HIPI, Paris, France; Department of Dermatology, DMU ICARE, AP-HP Saint-Louis Hospital, Paris, France.
Lancet Oncol ; 23(4): 491-500, 2022 04.
Article em En | MEDLINE | ID: mdl-35279271
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma de Kaposi Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Humans Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma de Kaposi Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Humans Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article